Adagene, Inc. (ADAG)
1.60
-0.11
(-6.43%)
USD |
NASDAQ |
Nov 16, 16:00
1.60
0.00 (0.00%)
After-Hours: 20:00
Adagene Enterprise Value : 194.71M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 194.71M |
| November 13, 2026 | 202.09M |
| November 12, 2026 | 221.57M |
| November 11, 2026 | 230.29M |
| November 10, 2026 | 224.92M |
| November 09, 2026 | 229.62M |
| November 06, 2026 | 221.57M |
| November 05, 2026 | 222.91M |
| November 04, 2026 | 249.09M |
| November 03, 2026 | 245.07M |
| November 02, 2026 | 241.04M |
| October 30, 2026 | 255.81M |
| October 29, 2026 | 267.22M |
| October 28, 2026 | 266.55M |
| October 27, 2026 | 260.51M |
| October 26, 2026 | 254.47M |
| October 23, 2026 | 249.09M |
| October 22, 2026 | 251.11M |
| October 21, 2026 | 249.09M |
| October 20, 2026 | 255.14M |
| October 19, 2026 | 241.04M |
| October 16, 2026 | 225.59M |
| October 15, 2026 | 248.42M |
| October 14, 2026 | 241.04M |
| October 13, 2026 | 252.45M |
| Date | Value |
|---|---|
| October 12, 2026 | 271.25M |
| October 09, 2026 | 272.59M |
| October 08, 2026 | 273.94M |
| October 07, 2026 | 275.95M |
| October 06, 2026 | 284.01M |
| October 05, 2026 | 275.28M |
| October 02, 2026 | 278.64M |
| October 01, 2026 | 284.01M |
| September 30, 2026 | 302.14M |
| September 29, 2026 | 302.81M |
| September 28, 2026 | 302.14M |
| September 25, 2026 | 284.01M |
| September 24, 2026 | 287.37M |
| September 23, 2026 | 286.70M |
| September 22, 2026 | 304.15M |
| September 21, 2026 | 302.81M |
| September 18, 2026 | 309.52M |
| September 17, 2026 | 313.55M |
| September 16, 2026 | 300.12M |
| September 15, 2026 | 286.70M |
| September 14, 2026 | 306.84M |
| September 11, 2026 | 315.57M |
| September 10, 2026 | 309.52M |
| September 09, 2026 | 306.84M |
| September 08, 2026 | 321.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascletis Pharma, Inc. | 567.37M |
| CStone Pharmaceuticals Co. Ltd. | 870.05M |
| RemeGen Co., Ltd. | 4.804B |
| InnoCare Pharma Ltd. | 2.178B |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -23.59% |
| Normalized Earnings Yield | -22.88 |